The right mix matters in biopharma leadership

The right mix matters in biopharma leadership

Source: 
Endpoints
snippet: 

Breaking the biopharma glass ceiling isn’t just a moral issue; it’s a shareholder issue. McKinsey reported in a recent study that companies in the top quartile for gender diversity are 15 percent more likely to generate financial returns above the industry average; those in the top quartile for racial and ethnic diversity are 35 percent more likely to do so.